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Abstract
Background: The quality of harms reporting in journal publications is often poor, which can impede the risk-benefit
interpretation of a clinical trial. Clinical study reports can provide more reliable, complete, and informative data on harms
compared to the corresponding journal publication. This case study compares the quality and quantity of harms data
reported in journal publications and clinical study reports of orlistat trials.
Methods: Publications related to clinical trials of orlistat were identified through comprehensive literature searches. A
request was made to Roche (Genentech; South San Francisco, CA, USA) for clinical study reports related to the orlistat
trials identified in our search. We compared adverse events, serious adverse events, and the reporting of 15 harms criteria
in both document types and compared meta-analytic results using data from the clinical study reports against the journal
publications.
Results: Five journal publications with matching clinical study reports were available for five independent clinical trials.
Journal publications did not always report the complete list of identified adverse events and serious adverse events. We
found some differences in the magnitude of the pooled risk difference between both document types with a statistically
significant risk difference for three adverse events and two serious adverse events using data reported in the clinical study
reports; these events were of mild intensity and unrelated to the orlistat. The CONSORT harms reporting criteria
were often satisfied in the methods section of the clinical study reports (70–90 % of the methods section criteria
satisfied in the clinical study reports compared to 10–50 % in the journal publications), but both document types
satisfied 80–100 % of the results section criteria, albeit with greater detail being provided in the clinical study reports.
Conclusions: In this case study, journal publications provided insufficient information on harms outcomes of clinical
trials and did not specify that a subset of harms data were being presented. Clinical study reports often present data
on harms, including serious adverse events, which are not reported or mentioned in the journal publications. Therefore,
clinical study reports could support a more complete, accurate, and reliable investigation, and researchers undertaking
evidence synthesis of harm outcomes should not rely only on incomplete published data that are presented in the
journal publications.
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Background
There are two driving concerns that continue to grow
when relying on published medical research to reflect
the truth [1]. First, trials often remain unpublished years
after completion, and the results are, therefore, unavail-
able to the public. Second, trials often display a distorted
representation, where publications present a biased or
misleading description of the design, conduct, or results
of a trial [2, 3].
Journal publications and registry reports currently rep-
resent the main information source for obtaining sum-
maries of clinical trial data for the purposes of clinical
and health policy decision-making [4]. Results in the
past have found reporting in journal publications to be
inadequate and inconsistent [5], and although clinical
trial registries have been responsible for making major
strides in improving the transparency of trial data, a
recent study suggested that the results from trial regis-
tries often remain unavailable [6].
The clinical study report (CSR) is a structured docu-
ment that summarises the analysis methods and results
of a clinical trial submitted for marketing authorization
of an investigational medicinal product in the European
Union, Japan, or the United States. CSRs are an ‘inte-
grated’ full report, which can be up to a thousand pages
in length, and include extensive detailed information on
the efficacy and harms of interventions. The information
in these documents relating to harms is usually separated
individually by adverse event (AE) and serious adverse
event (SAE) terms in summary tables and listings.
In the past, researchers have made major efforts to gain
access to CSRs, with the intention to inform regulatory
decision-making [7]. The information contained in the
CSRs has proved vital when evaluating both the efficacy [8]
and safety [9] of clinical interventions. Evidence from jour-
nal publications has previously been questioned, and even
overturned, by findings from unpublished information re-
ported in the CSR [10]. In December 2009, Roche was the
first global healthcare company to release ‘Clinical Study
Reports’ after growing concerns over their product Tamiflu
[8]. Their policy now allows researchers to access the CSRs
and summary reports used for regulatory purposes since 1
January 1999. In 2010, the European Medicine Agency
(EMA) [11] became the first major regulatory agency to
agree to an open-access policy to confidential documents,
including CSRs. However, in 2013, the EMA was forced to
step backwards when the general court of the European
Union (EU) ordered them to limit the access to their re-
ports due to legal cases from two drug companies [12]. In
October 2014, the EMA published their final policy on the
access to documents and CSRs [13].
Orlistat (trade name: Xenical) is marketed by Roche in
most countries. It is used in the treatment of obesity as
a selective inhibitor of gastric and pancreatic lipase [14].
Mild, but unpleasant, gastrointestinal (GI) side effects
are commonly reported with orlistat use. A recent re-
view [15], including 16 randomized placebo-controlled
trials of orlistat, estimated an increased risk of discontin-
uations due to AEs of 3 % (95 % CI 1–4 %) with orlistat.
The most common AEs leading to withdrawal were GI
(40 %); only eight (50 %) trials specified the number of
AEs due to GI problems. Another study [16] of 29 trials
of orlistat indicated an increase in the risk for diarrhoea,
flatulence, abdominal pain, and dyspepsia in orlistat-
treated patients compared with placebo. No SAEs were
reported in these reviews. Concern exists that there may
also be an associated increased risk of serious hepatic
events, as indicated in a case series study using primary
care data from the Clinical Practice Research Datalink
(CPRD) [17].
We aim to carry out an exploratory review consisting
of two main analyses: (1) to compare the number(s) of
reported harms (AEs and SAEs) and (2) the structured
reporting of harms. Both analyses will be assessed be-
tween CSRs and journal publications using a case study
of Roche-sponsored orlistat trials to provide a summary
of the added value, if any, from the CSRs. To our know-
ledge, an in-depth exploration that includes a detailed
meta-analysis of this type has not been published in pre-
vious CSR-related research.
Methods
We planned to identify independent trials, each of which
were reported within two different trial summary reports:
CSRs and publically available journal publications. The
aim was to compare these document types and determine
whether there were inconsistencies in the quality and
quantity of reporting of harms. The CSRs were released
by Roche (Genentech; South San Francisco, CA, USA).
Identifying the studies
A search was implemented by one researcher (AH) in the
Cochrane Central register (final search 6 July 2013) and
Ovid MEDLINE (final search 2 July 2013) to obtain all
relevant published, randomised, controlled trials compar-
ing orlistat against a placebo for obesity treatment. The
search strategies are provided in Additional file 1. Each
full article was assessed independently by one reviewer
(AH) to determine eligibility. We included published and
unpublished RCTs investigating the use of orlistat. No re-
striction was placed on the clinical area. Observational
studies and those studies that did not specify orlistat as
their primary intervention were excluded.
Data collection and extraction
Roche was contacted and asked to provide the corre-
sponding CSRs for each of the publications identified. A
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Roche CSR consists of the following five modules of
information:
Module I: The ‘Core report’ – background and rationale,
objectives, materials and methods, efficacy results, safety
results, discussion, conclusion and appendices
Module II: ‘Study documents’ – protocol and
amendment history, blank case report forms (CRFs),
subject information sheet and consent form, glossaries
of original and preferred terms, randomization list,
reporting analysis plan (RAP), certificates of analysis,
list of investigators and list of ethics committee
members
Module III: ‘Listings of demographic and efficacy data’
Module IV: ‘Listing of safety data’
Module V: ‘Statistical report and appendices’ – statistical
analysis and efficacy results
For each matching document pair (CSR and journal
publication), the following data were extracted:
 Content and characteristics of both document types,
including whether a clear primary objective of safety
was defined, a word count of the information relating
to harms in both the journal publication (including
any online supplementary material) and in the CSR
documents of text only (word count performed using
the software AnyCount version 7.0 [18]). Missing
pages relating to safety due to redactions were noted
in the results; we managed to obtain these on further
request.
 Name of each reported AE and SAE term recorded
for both placebo and orlistat, with the overall number
of patients in the safety population, as defined in the
respective document. The intensity grading (i.e. mild,
moderate, or severe), relationship to orlistat, and
definition of the SAEs were also observed where
possible. SAEs were defined as any event that was
fatal or life-threatening, requiring hospitalization or
prolongation of hospitalization, or an overdose. The
AE coding system was also detailed.
 Reporting structure of harms (CONSORT-harms [19]
used as a benchmark). The CONSORT extension for
reporting harm outcomes extends ten checklist items
of the CONSORT (2001) checklist to help support
the reporting of harms-related data from RCTs. This
includes guidance on how to report harms in the title
and abstract, introduction, methods (definitions,
collection, and analysis), results (withdrawals,
denominators, and type), and the discussion.
One researcher (AH) extracted, and a second reviewer
(CTS) checked the data extraction. Discrepancies in the
rates of agreement were resolved through consensus or
recourse to a third reviewer (CG), where necessary. As
there were no disagreements in the data extraction for
the first three trials (NM16189, M37013, and M37002),
extraction for the final two trials was only carried out by
one reviewer (AH).
AEs and SAEs
For a particular trial, all harms (AEs and SAEs) reported in
either the journal publication or the CSR were extracted
and compared across the two document types. The clinic-
ally validated medical terminology dictionary MedDRA is
commonly used during the regulatory process by all stake-
holders in healthcare; it is used for coding harm outcomes.
These reported outcomes were then organized into each of
the five levels of the MedDRA dictionary: the system organ
class, high-level group term, high-level term, preferred
term, and lowest level term. Outcomes are usually reported
in the journal publications and CSRs as MedDRA pre-
ferred term level events. Therefore, we compared the total
number of reported MedDRA preferred terms, and if a
preferred term was reported in both the CSR and journal
publication, the numerical data were compared, and any
discrepancies, noted.
For each MedDRA preferred term (AE and SAE), the
data extracted from the CSRs were used to estimate risk
differences, which were pooled across trials using fixed-
effect meta-analysis. A corresponding meta-analysis was
performed using the data extracted from the journal
publications wherever relevant. The pooled risk differ-
ence (RD) with 95 % confidence interval [20] and the I2
statistic [21] were compared between the CSR-based and
the journal publication-based analyses. As the SAE data
were sparse, a sensitivity analysis was undertaken to pool
the relative risk (RR). We stress that these meta-analysis
results are based on a subset of the eligible trials of orli-
stat and are presented for the purpose of methodological
comparison rather than definitive clinical results.
Structured reporting of harms
Using the CONSORT-harms extension [19] as a bench-
mark for reporting harms data from a randomised con-
trolled trial, documents were assessed across 15 adapted
criteria (see Table 1) that focus on the methods and
results. Each trial was classified as follows for each indi-
vidual criteria:
BOTH – both documents report the criteria
CSR – only reported criteria in the clinical study report
Pub – only reported criteria in the trial publication
NR – criteria not reported in either document
The total number of criteria satisfied in each CSR and
journal publication for a particular trial was calculated
and expressed as a percentage of 15 criteria.
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When both document types reported on any particular
individual criteria (i.e. BOTH), the reported information
was compared and classified as follows:
CSR (+) – The CSR provides more information than
the journal publication
Similar (O) – Both document types provide equal and
similar information
CSR (-) – The journal publication provides more
information than the CSR
Results
Thirty-one journal publications related to 31 randomised
controlled trials of orlistat were identified in our search
(Fig. 1). We requested access to the full CSRs from Roche
corresponding to each of these trials. The CSRs could not
be provided for 26 of these trials. Of the 26 trials, 17 were
not Roche-sponsored, and therefore, the CSRs were not
held by Roche. Nine trials pre-dated Roche’s policy exten-
sion, which only allows access to trials dating back to 1
January 1999.
CSRs were obtained and matched with the correspond-
ing journal publication for five trials (NM16189 [17],
M37013 [18], M37002 [19], M37047 [20], and BM15421
[21]). Module I of the CSR was provided for all trials.
Module II was not provided for one trial (BM15421), and
module V was not provided for one trial (NM16189). We
contacted Roche to provide reasons for these missing
modules and for the four missing pages. Roche informed
us that these sections contained confidential information
and had to be removed. Modules III and IV were not pro-
vided for any of the trial CSRs because they contained in-
dividual patient data listings.
Table 2 shows the content and characteristics for each
trial document pair. Safety was not the primary objective
for any of the five trial journal publications but was de-
fined as a secondary objective in three journal publications
[22–24] and was not specified in two journal publications
[25, 26]. Two trials [23, 25] were published in the Journal
of Diabetes, Obesity and Metabolism; two trials [24, 26],
in the Journal of Diabetes Care; and one trial [22], in the
Journal of the American Medical Association (JAMA).
The mean word count across the five trial journal pub-
lications was 7,265 (standard deviation (sd) 1,894), with
an average of 10 % of words (mean (sd) 757 (287)) dedi-
cated to safety. The CSRs had a mean (sd) of 163,411
(96,872) words across all trials, with approximately 3 %
(mean (sd) 4,663 (1,446)) related to safety. The mean dif-
ference between the CSR and journal publication was
3,906 (95 % CI (1,756; 6,056)) words.
Comparison of reported AE and SAE event data
MedDRA version 2.3 had been used to code AEs and
SAEs in all five trials.
Table 1 Fifteen criteria (adapted from the CONSORT-harms extension) assessed to evaluate the completeness of reporting methods
and results of harms
Criteria Criteria description Description of complete reporting for criteria
Methods 1 List addressed adverse events with definitions Listed AEs with definitions (with attention to the grading, when relevant)
2 Mode for collecting data Full description of questionnaires, interviews, or tests used to collect information
on the harms. Detailed information on the questions asked
3 Timing and time frame of surveillance Description of the time frame of surveillance for AEs, with the stopping period
detailed
4 Attribution methods Person responsible for making attribution disclosed and whether blinding was
used
5 Intensity of ascertainment Specify clearly how the withdrawals are handled in the analyses
6 Harms-related monitoring Plans for monitoring and rules for stopping for the benefits and harms
separately
7 Coding of AEs Reference to any coding system used and person responsible for the coding
8 Handling of recurrent events Specify how recurrent events are handled: detailed as separate events or as one
9 Timing issues Timing of events explained, if recurrent
10 Plans to perform any statistical analyses and
inferences
Described how pre-specified statistical analyses are separated from post hoc
analyses, and any common problems addresses
Results 11 Withdrawals and discontinuations Reasons for discontinuations and separated by arm. Flow diagrams used to
display withdrawals
12 Denominators for analyses on harms Analyses and definitions used and clearly stated (i.e. intention to treat (ITT)),
and all denominators for safety population are clearly detailed
13 Specifying AE type Results presented separately by System Organ Classification type
14 Grading or scaling used Each AE type should offer appropriate metrics of absolute risk
15 Seriousness per arm Reported separately for each type of event
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Fig. 1 Flow diagram for obtaining the trial reports
Table 2 Content and characteristics of the trial documents
Trial ID NM16189 M37013 M37002 M37047 BM15421
Safety primary objective of trial? No† No† No¥ No¥ No†
Journal publication: author,
journal and year
Chanoine [22], Journal
of the American Medical
Association (JAMA (2005)
Halpern [23], Diabetes,
Obesity and Metabolism
(2003)
Hanefeld [25], Diabetes,
Obesity and Metabolism
(2002)
Kelley [26], Diabetes
Care (2002)
Torgerson [24],
Diabetes
Care (2004)
CSR research report no.
(date of CSR)
1011426 (2003) 1002688 (2000) 1003882 (2001) 1002743 (2001) 1008213 (2002)
Word count (including text and numbers, but not tables)
Trial document Pub CSR Pub CSR Pub CSR Pub CSR Pub CSR
Total number of words
in document
10,568 146,801 6,371 45,464 6,382 140,166 7,090 170,347 5915 314,277
Total number of words relating
to safety (% of total)
1,147 (10.9) 4,883 (3.3) 908 (14.3) 2,664 (5.9) 638 (10) 4,964 (3.5) 707 (10) 4,150 (2.4) 387
(6.5)
6,653
(2.1)
CSR Moduleɸ supplied by
Roche
I ✓Π ✓Π ✓ ✓Π ✓Π
II ✓ ✓ ✓ ✓ *
III * * * * *
IV * * * * *
V * ✓ ✓ ✓ ✓
Footnote:
CSR Clinical study report, Pub Journal publication
†Safety secondary objective in both the CSR and journal publication; ¥Objective to assess improvements in glycaemic control and cardiovascular disease risk in
both CSR and Journal publication; ɸModule: I = Core report (background and rationale, objectives, materials and methods, efficacy results, safety results,
discussion, conclusion and appendices); II = Study documents (protocol and amendments history, black case report form (CRF), subject information sheet and
consent form, glossaries of original and preferred terms, randomization list, reporting analysis plan (RAP), certificates of analysis, list of investigators, list of ethics
committee members); III = Listing of demographic and efficacy data; IV = Listing of safety data; V = Statistical reports and appendices (Statistical analysis, efficacy
results). ✓Module provided in CSR; *Roche did not provide these modules, since they contained individual patient data listings and therefore were deleted. ϵ We
could only count words for modules that were made available by Roche, so the actual number would be greater than this. The percentage of words relating to
harms would therefore differ; Π CSRs each had one missing page in module I, which Roche provided upon further requests. Any additional information from this
was used in the results.
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Adverse events
The total number of MedDRA preferred terms for AEs
varied across trials (Fig. 2) (Forest plots are provided in
Additional file 1). The journal publications did not
always report the complete list of terms identified in the
corresponding CSR, but all of these ‘missing’ AEs were
of mild to moderate intensity and were unrelated to the
intervention. For instance, in one trial (M37013), very
good consistency in reporting was observed between the
CSR and journal publication, with 18 AEs reported in
total, 18 (100 %) of which were listed in the CSR and 17
(94 %) in the journal publication. However, very poor
consistency was observed for the three trials (M37002,
M37047, and BM15421), with 5 % or fewer of the total
AEs being reported in the journal publication (M37002,
one (5 %); M37047, one (4 %); BM15421, 0 (0 %)). When
a MedDRA preferred term was listed in both the CSR
and journal publication, complete agreement was ob-
served in the numerical results (Additional file 2) except
for one trial (M37013), where three additional patients
with ‘abdominal pain’ on orlistat were identified within
the journal publication.
In the meta-analysis (MA) for the AEs (Table 3), 61
individual MedDRA preferred terms were reported in
either the CSR or journal publication across the five tri-
als (Additional file 1). Thirty (49 %) of these terms were
reported in the CSR and corresponding journal publica-
tion for at least one trial, thereby allowing a comparison
of the pooled results. In six (20 %) of the 30 MA com-
parisons, the magnitude of the effect differed (the 95 %
CI for the pooled risk difference (RD) did not overlap
between the CSR and the journal publication results).
These include the AE terms: ‘increased defecation’, ‘oily
spotting’, ‘oily evacuation’, ‘faecal incontinence’, ‘soft stools’,
and ‘faecal urgency’. For the 31 AE terms that had only
been reported in a CSR, 23 (74 %) analyses suggested an
increased risk of an AE on orlistat, two (6 %) of which
were statistically significant (faeces discolouration and dry
skin); these AEs were mild and were unrelated to treat-
ment. For four (13 %) terms, an increased risk of an event
occurred with the placebo, one (3 %) of which was statisti-
cally significant (haemorrhoids) and of a mild grade.
Serious adverse events
The total number of MedDRA preferred terms for SAEs
were generally poorly reported in journal publications
(Fig. 3; Additional file 3). For the four trials (M37013,
M37002, M37047, and BM15421) only 11 % or fewer of
the total SAE terms were reported in the journal publica-
tion with 11 %, 0 %, 0 %, and 0 %, respectively. All SAEs
that were reported only in the CSR were of mild intensity
grading and were unrelated to the treatment.
In trial NM16189, 19 SAE terms were reported across
the CSR and journal publication. Thirteen of these were re-
ported in both documents, either with full numerical
agreement (12 SAE terms) or with disagreement in numer-
ical results (one depression SAE on orlistat reported in the
CSR, and two depression SAEs reported in the journal
publication) (Additional file 3). Five SAE terms were only
reported in the CSR (demyelination (one) and broncho-
spasm aggravated (one) on placebo, and convulsions (one),
suicidal ideation (one) and liquid stools (one) on orlistat).
Encephalomyelitis as an SAE was reported for placebo in
the publication but not the CSR. Trial M37013 reports
nine SAEs, with only “diarrhoea and dehydration” on orli-
stat reported in both documents. The remaining eight
Fig. 2 The total number of MedDRA preferred terms (Adverse Events) reported in clinical study reports (CSRs) and journal publications across all
five trials. Footnote: Total: Total number of individual MedDRA preferred terms related to AEs reported across the CSR and journal publication for
a trial
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SAEs were only reported in the CSR; death (one), diabetes
mellitus (one), hysterectomy and perineoplasty (one), mi-
tral lesion (one) on placebo and Chronic cholecystitis
(one), nephrectomy due to previous renal carcinoma (one),
nephrectomy and lithotripsy due to previous nephrolithia-
sis (one), ovary carcinoma and ascites (one) on orlistat.
The three remaining trials (M37002, M37047, and
BM15421) report a high number of SAEs (40, 53, and 255)
within the CSR that have not been reported in the corre-
sponding journal publication.
In the MA for the SAEs (Table 4), 326 individual terms
were reported in either the CSR or journal publication
across the five trials (Additional file 4). Fourteen (4 %) of
these terms were reported in the CSR and corresponding
journal publication for at least one trial, allowing a com-
parison of the pooled results. For the 311 (95 %) terms
that had only been reported in a CSR, 16 (5 %) analyses
suggested an increased risk of an SAE on orlistat, two
(13 %) of which were statistically significant (carotid
artery stenosis and varicose veins), but all were mild
and unrelated. In the sensitivity analysis, pooling rela-
tive risk rather than risk differences, no SAEs were
found to be statistically significant. However, we were
unable to estimate the pooled relative risk for ten AEs
(including carotid artery stenosis and varicose veins), as
they include multiple studies reporting no events in the
placebo group.
Structured reporting of harms
The quality of reporting harms-related information, as
assessed against the 15 criteria adapted from the
CONSORT-harms checklist, are displayed in Table 5.
The CSRs satisfied 70–90 % the methods related cri-
teria across the five trials compared to the journal
Table 3 Summary of meta-analysis results for the individual MedDRA preferred term adverse events pooled across all five trials
Adverse events (AEs) Breakdown of adverse events reporting
Meta-analysis characteristic Total Once in the clinical study report (CSR)
and journal publication
CSR Journal publication
Number of AE terms reported
(% of total)
61 30 (49 %) 31 (51 %) 0 (0)
Direction of pooled risk effect
in meta-analysis
For all 30 AEs there is agreement in
direction of the pooled risk effect
between the pairing of documents
• 23 (74 %) showed an increased pooled risk
of AE on orlistat
• four (13 %) showed no difference
• four (13 %) showed increased pooled risk
of AE on placebo
AE listings for when there is
a change in effect including
statistical significance
• Pooled risk effect was greater in
journal publication for four AEs;
increased defecation, oily spotting,
oily evacuation, faecal incontinence
• Pooled risk effect was greater in
the CSR for two AEs; soft stools,
faecal urgency
• two (6 %) of the 23 AEs were statistically
significant; faeces discolouration, dry skina
• one (3 %) of the four AEs with
increased risk on placebo was statistically
significant; haemorrhoidsa
Footnote:
aThese adverse events were mild and unrelated to treatment
Fig. 3 The total number of serious adverse events reported in the clinical study reports (CSRs) and journal publications across all five trials. Footnote: Total:
Total number of individual MedDRA preferred terms related to SAEs reported across the CSR and journal publication for a trial
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publications, which satisfied between 10 % and 50 %.
The CSRs consistently provided much greater detail re-
garding planned analyses than the journal publication,
and on only one occasion did the journal publication
provide greater detail than the CSR (trial M37013; item
3 timing and time frame of surveillance for AEs). Both
the CSRs and the journal publications satisfied 80–100
% of criteria in their results sections, but greater detail
was generally provided in the CSR. This included full
summary tables of the AE and SAE data, including
Table 4 Summary of meta-analysis results for the individual MedDRA preferred term serious adverse events pooled across all five trials
Serious Adverse Events (SAEs) Breakdown of serious adverse events reporting
Meta-analysis characteristic Total Once in the clinical study report (CSR)
and journal publication
CSR Journal publication
Number of SAE terms
reported (% of total)
326 14 (4 %) 311 (95 %) 1 (<1 %)
Direction of the pooled risk
effect in the meta-analysis
For all 14 SAEs, there is agreement
in direction of the pooled risk effect
between the pairing of documents
• 16 (5 %) showed increased pooled risk of
SAE on orlistat
• 281 (90 %) showed no difference
• 14 (5 %) showed an increased pooled risk
of SAE on placebo
The one SAE showed
increased pooled risk
on placebo
SAE listings for when there
is a change in effect including
statistical significance
Two (13 %) of the 16 SAEs were
statistically significant; carotid artery
stenosis, varicose veinsa
One SAE; encephalomyelitis
was statistically
non-significant
Footnote:
aThese serious adverse events were mild and unrelated to treatment
Table 5 Comparison of 15 harms criteria (CONSORT-harms extension used as a benchmark)
Trial ID
Criteria Description of item NM16189 M37013 M37002 M37047 BM15421
Methods criteria 1 List addressed adverse events (AEs) with definitions. CSR CSR CSR CSR CSR
2 Mode of collecting harms data. BOTH b BOTH b BOTH b CSR BOTH a
3 Timing and time frame of surveillance for adverse events. BOTH b Pub CSR NR BOTH a
4 Attribution methods. CSR NR CSR NR NR
5 Intensity of ascertainment. CSR BOTH b CSR CSR CSR
6 Harms related monitoring. CSR BOTH b CSR CSR CSR
7 Coding of AEs. CSR CSR BOTH a CSR CSR
8 Handling of recurrent events. NR CSR NR CSR NR
9 Timing issues. CSR CSR CSR NR CSR
10 Plans to perform any statistical analyses and inferences. CSR BOTH a BOTH a BOTH a BOTH a
Total items satisfied for methods criteria in clinical study report (CSR) (% of total
10 items assessed)
9 (90) 8 (80) 9 (90) 7 (70) 8 (80)
Total items satisfied for methods criteria in publication (% of total ten items
assessed)
2 (20) 5 (50) 3 (30) 1 (10) 3 (30)
Results criteria 11 Withdrawals and discontinuations. BOTH a BOTH a BOTH a BOTH a CSR
12 Denominators for analyses on harms. BOTH b BOTH b BOTH a CSR BOTH b
13 Specifying AE type. BOTH a BOTH a BOTH a BOTH a BOTH a
14 Grading or scaling used. NR BOTH a BOTH a BOTH a BOTH a
15 Seriousness per arm. BOTH a BOTH a BOTH a BOTH a BOTH a
Total items satisfied for results criteria in the CSR (% of total five items assessed) 4 (80) 5 (100) 5 (100) 5 (100) 5 (100)
Total items satisfied for results criteria in the publication (% of total five items
assessed)
4 (80) 5 (100) 5 (100) 4 (80) 4 (80)
Total items satisfied in CSR (% of total 15 items assessed) 13 (87) 13 (87) 14 (93) 12 (80) 13 (87)
Total items satisfied in publication (% of total 15 items assessed) 6 (40) 10 (67) 8 (53) 5 (33) 7 (47)
Footnote:
BOTH ‘reported in CSR and the corresponding journal publication’, CSR ‘only reported within the CSR’, Pub ‘only reported in journal publication’, NR ‘neither
reported in the CSR or journals publication’. Completeness of data where agreement (BOTH) is made coded as: a ‘More complete in CSR’; b ‘Similar quality for both
documents’; - ‘less complete in the CSR’
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withdrawals due to harm, severity grading, and denomina-
tors for the numbers included in the safety population.
Discussion
This case study has shown differences in the complete-
ness and quality of reporting harms-related information
between journal publications and CSRs for five orlistat
trials. Information on the patient-relevant harm out-
comes, including SAEs, which is required for unbiased
trial evaluation, was missing from the publicly available
journal article. Including these missing data from the
CSRs altered the magnitude of the pooled risk difference
estimates in a few cases and even resulted in five statisti-
cally significant differences (including three AEs and two
SAEs). The statistically significant risk differences for
AEs were faeces discolouration, dry skin, and haemor-
rhoids, and for SAEs, carotid artery stenosis and varicose
veins. However, the statistical significance of these SAEs
could not be confirmed in a sensitivity analysis pooling
relative risks [27, 28] due to zero events. The events were
graded mild and were classified as unrelated to treatment.
Overall, the results from the journal publications in this
study follow findings from past studies [15, 16], with a
more detailed meta-analysis showing predominantly mild
gastrointestinal harm outcomes.
The quality of reporting between journal publications
and CSRs showed inconsistencies when assessed by the
CONSORT-harms reporting criteria. At 70–90 %, the
methods section criteria were more often satisfied in the
CSRs, compared to only 10–50 % of the criteria in the
journal publications. However, both document types satis-
fied 80–100 % of the results section criteria, albeit with
greater detail being provided in the CSR. The journal pub-
lication was often incomplete when reporting planned
analyses and summary tables of AEs and SAEs, which
were missing information on withdrawals, severity grad-
ing, and numbers in the safety population. Journal publi-
cations are often impeded by word count restrictions.
However, inadequate reporting of harms is still noticeable,
even after the release of the CONSORT-harms extension
[19], as the findings from our recent review [29] suggest.
In contrast, CSRs have no such word restrictions imposed,
and theoretically, all relevant information should be
included. An alternative and more viable solution appears
to be that journals should require more thorough report-
ing of harms via online supplements (e.g. de-identified
CSRs, study protocols, and complete tables of AE-related
information) [30].
In a recent study [4], findings on harms information ob-
tained from the CSRs were found to be more complete
and robust compared with the corresponding publically
available sources (journal publications and registry reports).
More than 86 % of all harm outcomes (AEs and SAEs)
were available from the CSRs, compared to only 26 % from
the journal publications. Combining harms data from
registry reports and journal publications increased the pro-
portion of outcomes to 43 %. Furthermore, withdrawals
due to AEs were detailed completely in 91 % of the CSRs,
with only 51 % of the journal publications providing
complete information. In another study [31], inadequate
reporting of the harms was shown in the Medtronic manu-
factured product, recombinant human bone morpho-
genetic protein 2 (rhBMP-2), used in spinal fusion surgery.
As in our investigation, harms data were found to be miss-
ing from the publications, with considerably more data
found in the corresponding trial CSRs. Further evidence of
poor reporting of benefits and harms was found in a recent
investigation of the product duloxetine in patients with
major depressive disorder [32]. The CSRs contained ex-
tensive data on major harms that were unavailable in
the journal publications and in trial registry reports.
Restricting evidence synthesis to journal publications
would effectively miss these important harms. Further
empirical comparisons such as ours, in different clinical
areas, would be valuable.
The drive to make clinical trial data more accessible has
garnered widespread international support, with funders,
academics, pharmaceutical industry, publishers and regu-
lators supporting the move towards greater transparency.
For example, the BMJ recently stated that it will no longer
publish trials of drugs or devices where the authors do not
commit to making the relevant anonymised patient-level
data available; this was to be extended to all submitted
clinical trials beginning 1 July 2015. In addition, the EMA
has now adopted their new policy, making clinical trials
data more accessible [13], including access to full CSRs.
Roche should also be commended for voluntarily submit-
ting their data and allowing further access to their CSRs.
The new EU clinical trial regulation [33] published on 27
May 2014 also states under section (67) that ‘trial data
should be publically accessible and presented in an easily
searchable format, with related data and documents
(including trial protocol and CSR) linked together by
the EU trial number’.
Our study has a number of limitations. First of all, the
meta-analysis results do not provide comprehensive un-
biased clinical results, as they are based only on a subset
of the five eligible orlistat trials, due to the inability to ob-
tain CSRs for the remaining 26 identified trials, which
were not Roche sponsored or pre-dated Roche’s policy
(dating back to 1 January 1999). The meta-analyses were
conducted without any adjustment for multiplicity, mean-
ing that there is an increased chance of a false positive re-
sult, and the results should be interpreted with caution. In
addition, for the five CSRs obtained from Roche in this
study, some of the reports failed to include any informa-
tion from modules II, III, IV, and V, and some had missing
pages. Individual participant-level data and potentially
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other important information on harms are often pre-
sented in Roche’s CSR modules III-V. Access to these
modules and confidential patient listings may have been
restricted due to privacy violations, and these missing
sections could present a possible cause of bias in the
results. In a recent study [34], reviewers re-analysed
one of SmithKline Beecham’s studies by requesting and
accessing the full individual participant level data sets
to compare the efficacy and safety of paroxetine. The
findings from this study support the necessity of mak-
ing trial individual participant-level data and protocols
available to help evidence-based decisions. In module I
of the CSRs, they also detailed that only commonly ob-
served AEs (defined as those events with incidence rate
in orlistat group of ≥ 5 %) were summarized, indicating
that there are potentially more unreported AEs missing
from the primary trial data. Therefore, the results in
this study were based only on the information available.
Conclusions
This case study confirms that CSRs can provide more
complete and robust information on harms data collected
in clinical trials, compared to publically available journal
publications. CSRs often provide extensive information
about the study methods, including design, conduct, and
analysis of the trial. On the other hand, these reports are
able to supplement journal publications to help facilitate
the assessment of risk of bias in evidence synthesis of
harm outcomes. Consequently, restricting an evidence
synthesis to journal publications could have implications
to systematic reviewers and other stakeholders involved in
healthcare research when reaching reliable conclusions
about the harmful effects of medical interventions.
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